The adjuvant immunotherapy trials' RFS endpoint was unsuccessful.

Published Date: 01 Aug 2023

According to a recent analysis, relapse-free survival in adjuvant immunotherapy trials for a variety of cancer types is a subpar surrogate endpoint for overall survival.

Read Full News

Latest News

Rheumatologist Shortage to Hit Nonmetropolitan Areas Hardest

Workforce projections show an uneven distribution of rheumatologists in the US, with notable shortages in nonmetropolitan areas and certain states and districts.

Epcoritamab Shows Promise in Frail Older Adults With LBCL

A phase 2 trial assesses fixed-duration epcoritamab monotherapy as first-line therapy for frail older adults with newly diagnosed anthracycline-ineligible large B-cell lymphoma.

A Man With a Recurrent Scalp Tumor

A recurrent scalp mass initially diagnosed as a pilomatrixoma is ultimately found to be a rare adnexal malignancy, underscoring the need for histologic precision.

US Nuclear Power Regulator Proposes Changing Rule Protecting People From Radiation

The U.S. nuclear power regulator on Wednesday proposed changes to a rule protecting people from radiation, the latest proposal pushed by the Trump administration to change...

AI-Generated Presentations: Can Better Prompts Save Time?

Structured prompts help physicians prepare conference presentations faster, but expert review remains essential to verify evidence, references, and scientific accuracy.

Higher Daytime Light Exposure Linked to Lower Dementia Risk

Exposure to relatively bright daytime light is linked to lower dementia risk and may provide a novel, measurable method to identify individuals at high risk for dementia.

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Latest News

Workforce projections show an uneven distribution of rheumatologists in the US, with notable shortages in nonmetropolitan areas and certain states and districts.

A phase 2 trial assesses fixed-duration epcoritamab monotherapy as first-line therapy for frail older adults with newly diagnosed anthracycline-ineligible large B-cell lymphoma.

A recurrent scalp mass initially diagnosed as a pilomatrixoma is ultimately found to be a rare adnexal malignancy, underscoring the need for histologic precision.

The U.S. nuclear power regulator on Wednesday proposed changes to a rule protecting people from radiation, the latest proposal pushed by the Trump administration to change...

Structured prompts help physicians prepare conference presentations faster, but expert review remains essential to verify evidence, references, and scientific accuracy.

Exposure to relatively bright daytime light is linked to lower dementia risk and may provide a novel, measurable method to identify individuals at high risk for dementia.

News All Time

PSA Testing Tied to Lower Risk for Prostate Cancer Mortality

Men who undergo prostate-specific antigen testing in the absence of symptoms have a lower risk for mortality due to prostate cancer than those who do not undergo the testing.

ADHD Medicine Prescribing Rises Beyond Childhood in Poland

Prescription rates for attention-deficit/hyperactivity disorder medications are rising sharply in Poland, with the fastest increases seen among young adults, particularly women.

Study Shows Impact of Loss of Copay Aid for Retina Drugs

Study finds cuts to copay aid for retina injections has patients switching to off-label treatments, paying more out of pocket, and going to the doctor’s more frequently.

Preservatives and Cancer: What Clinicians Should Know

Don't let relative risk statistics alarm you. While preservative associations appear significant, the actual absolute risk increase for cancer by age 60 is only about 1 to 1.5%.

Proton Therapy for Prostate Cancer: Key Takeaways

Don't get lost in the physics of proton beams. For prostate cancer, the quality of your multidisciplinary program and treatment execution is ultimately more impactful than the modality used.

EHR Burden Is Real: 3 Tips for Oncologists

The secret to fighting EHR burnout isn't just about faster clicks; it’s about using technology to automate routine administrative tasks so physicians can focus solely on complex clinical judgment.

Diet Still Matters After Alzheimer’s Pathology Occurs

A healthier diet, particularly one with lower inflammatory potential, was linked to a lower risk for dementia even among older adults with Alzheimer’s disease pathology.

How New Therapies Are Reshaping HER2+ Breast Cancer

Once a uniformly aggressive subtype, HER2+ breast cancer is now a proving ground for the most innovative therapies in oncology.

Deep Dive: Treatment or Surgery First in Pancreatic Cancer?

Pancreatic cancer's neoadjuvant debate is no longer about whether systemic therapy matters. It is about when to give it.

Fecal Transplant Offers No Clear Benefit in IBS

Fecal microbiota transplantation offers no clear benefit in reducing symptoms of irritable bowel syndrome, a meta-analysis finds.

Should Type 2 Patients Not on Insulin Use Glucose Monitors?

While research shows some blood glucose benefits, perhaps the biggest benefit comes from lifestyle changes.

AAP Guidance Seeks to Prevent Iron Deficiency Anemia

The new recommendations include universal screening for teens girls, who are at a high risk for iron deficiency and iron deficiency anemia.

Personality Symptoms May Be Linked to Nutritional Issues

Patients who report cravings, cognitive issues, or low energy may benefit from a deep nutrition examination.

Surgery or Hormonal Therapy for Rectovaginal Endometriosis?

Women with rectovaginal endometriosis show similar improvements in pain, function, and quality of life with either surgery or hormonal therapy, supporting a more individualised treatment approach.

PSMA-PET-CT May Allow Some Men to Skip Prostate Biopsy

Phase 3 data suggest PSMA-PET-CT could reduce unnecessary prostate biopsies in selected high-risk men, though longer follow-up is needed.

Bioterrorism and Disaster Medicine

This collection of news, notices, articles, and related links provide healthcare professionals with the latest information and resources related to caring for those affected by volatile world events such as terrorist attacks, war, and natural disasters.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Smart exercise planning could boost recovery for people with cancer

Alternative Medicine for Breast Cancer: Study Raises Concern

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

4.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

5.

A promising medication could slow brain tumors in children.

1.

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025

2.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

3.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases

5.

Generative AI for Adaptive Oncology Trial Design

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot